The 24 references in paper E. Stolyarevich S., L. Artyukhina Yu., E. Ivanova S., N. Tomilina A., Е. Столяревич С., Л. Артюхина Ю., Е. Иванова С., Н. Томилина А. (2017) “ИСПОЛЬЗОВАНИЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ПЛАЗМАФЕРЕЗОМ, ВНУТРИВЕННЫМ ЧЕЛОВЕЧЕСКИМ ИММУНОГЛОБУЛИНОМ И РИТУКСИМАБОМ ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ОТТОРЖЕНИЯ ТРАНСПЛАНТИРОВАННОЙ ПОЧКИ // USE OF COMBINED THERAPY BY PLASMAPHERESIS, HUMAN INTRAVENOUS IMMUNOGLOBULIN AND RITUXIMAB FOR CHRONIC RENAL ALLOGRAFT REJECTION” / spz:neicon:nefr:y:2016:i:6:p:67-74

1
Colvin RB et al. Diagnostic Pathology: Kidney Diseases. Amirsys; Salt Lake City: 2011
(check this in PDF content)
2
Colvin RB, Nickeleit V. Heptinstall’s Pathology of the Kidney. Jennette JC, Olson JL, Schwartz MM, Silva FG editors. Vol. 2. Lippincott-Raven; Philadelphia: 2006. Р.1347-1490
(check this in PDF content)
3
Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria – an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708–714
(check this in PDF content)
4
Sis B, Mengel M, Haas M et al. Banff ‘09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010;10(3):464-471
(check this in PDF content)
5
Gloor J, Cosio F, Lager DJ et al. The spectrum of antibodymediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367–1373
(check this in PDF content)
6
Sis B, Campbell PM, Mueller T et al Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007 Jul;7(7):1743-1752
(check this in PDF content)
7
Jordan SC, Quartel AW, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998 Sep 27;66(6):800-805
(check this in PDF content)
8
Everly MJ, Everly JJ, Arend LJ et al. Reducing De Novo Donor-Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss. American Journal of Transplantation 2009;
(check this in PDF content)
9
5): 1063–1071 9. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000 Sep 27;70(6):887-895
(check this in PDF content)
10
Rocha PN, Butterly DW, Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490–1495
(check this in PDF content)
11
Smith RN, Malik F, Goes N et al Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol 2012;27(2-3):107-113. doi: 10.1016/j.trim.2012.08.005. Epub 2012 Aug 30
(check this in PDF content)
12
Billing H, Rieger S, Susal C et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 2012; 25: 1165
(check this in PDF content)
13
Fehr T1, Rüsi B, Fischer A et al. Rituximab and intravenous immunoglobulin treatment of chronic antibodymediated kidney allograft rejection. Transplantation 2009 Jun 27;87(12):1837-1841
(check this in PDF content)
14
Rostaing L, Guilbeau-Frugier C, Fort M et al. Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int 2009; 22: 906
(check this in PDF content)
15
Bachelet T, Nodimar C, Taupin J-L. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study. Clin Transpl 2015; 29 (5): 439–446
(check this in PDF content)
16
Gloor JM, Sethi S, Stegall MD et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124
(check this in PDF content)
17
Kieran N, Wang X, Perkins J et al Combination of Peritubular C4d and Transplant Glomerulopathy Predicts Late Renal Allograft Failure. J Am Soc Nephrol 2009 October; 20(10): 2260–2268
(check this in PDF content)
18
Haririan A, Kiangkitiwan B, Kukuruga D et al. The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant 2009; 9: 2758
(check this in PDF content)
19
Kedainis RL, Koch MJ, Brennan DC et al. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant
(check this in PDF content)
20
9; 9: 812–819 20. Kayler LK, Kiss L, Sharma V et al. Acute renal allograft rejection: diagnostic significance of focal peritubular capillary C4d. Transplantation 2008;85(6):813-820
(check this in PDF content)
21
Hong YA, Kim HG, Choi SR et al. Effec tiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. Transplant Proc 2012;44:182-184
(check this in PDF content)
22
An GH, Yun J, Hong YA. The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. J Immunol Res 2014;2014:828732. doi: 10.1155/2014/828732. Epub 2014 Jan 29
(check this in PDF content)
23
Zarkhin V, Lovelace PA, Li L et al. Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients. Transplantation 2011;91(9):1010–1018
(check this in PDF content)
24
Lefaucheur C, Nochy D, Andrade J et al. Comparison of Combination Plasmapheresis/IVIg/Anti-CD20 Versus HighDose IVIg in the Treatment of Antibody-Mediated Rejection. Am J Transplant 2009; 9 (5): 1099-1107 Сведения об авторах:
(check this in PDF content)